Equities Analysts Set Expectations for BAX Q2 Earnings

Posted by George Bondi on May 22nd, 2026

Baxter International Inc. (NYSE:BAX – Free Report) – Equities research analysts at Zacks Research decreased their Q2 2026 earnings per share estimates for Baxter International in a note issued to investors on Thursday, May 21st. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.37 per share for the quarter, down from their previous estimate of $0.43. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $1.92 per share. Zacks Research also issued estimates for Baxter International’s Q3 2026 earnings at $0.52 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $1.87 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.55 EPS, FY2027 earnings at $1.91 EPS and Q1 2028 earnings at $0.40 EPS.

BAX has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Baxter International in a research note on Friday, May 15th. Barclays raised their target price on shares of Baxter International from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. The Goldman Sachs Group lifted their price target on Baxter International from $17.00 to $19.00 in a report on Friday, May 1st. Jefferies Financial Group lowered their price target on Baxter International from $21.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, February 13th. Finally, TD Cowen cut their price objective on Baxter International from $22.00 to $20.00 in a research report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $19.91.

Get Our Latest Analysis on Baxter International

Baxter International Price Performance

Shares of BAX opened at $19.05 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. The company’s fifty day simple moving average is $17.45 and its 200 day simple moving average is $18.73. Baxter International has a 1-year low of $15.73 and a 1-year high of $32.04. The company has a market cap of $9.84 billion, a price-to-earnings ratio of -8.94, a PEG ratio of 3.02 and a beta of 0.62.

Baxter International (NYSE:BAX – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. The company had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.62 billion. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The business’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, May 29th. Baxter International’s payout ratio is currently -1.88%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BAX. Basepoint Wealth LLC acquired a new position in Baxter International in the 4th quarter valued at $26,000. Imprint Wealth LLC acquired a new stake in shares of Baxter International during the third quarter worth $27,000. MUFG Securities EMEA plc bought a new stake in shares of Baxter International in the second quarter valued at about $46,000. Los Angeles Capital Management LLC acquired a new position in shares of Baxter International in the fourth quarter valued at about $46,000. Finally, McMillan Office Inc. acquired a new position in shares of Baxter International in the fourth quarter valued at about $54,000. 90.19% of the stock is owned by institutional investors and hedge funds.

Baxter International Company Profile

(Get Free Report)

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.